Kevin Appourchaux
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kevin Appourchaux has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Susruta Majumdar
Center for Clinical Pharmacology, Department of Anesthesiology and Washington University Pain Center, Washington University School of Medicine, Saint Louis, MO, USA
8 shared publications - Tao Che
Center for Clinical Pharmacology, Department of Anesthesiology, Washington University School of Medicine, St. Louis, USA
6 shared publications - Jay P. McLaughlin
Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, USA
5 shared publications Amal El Daibani
Center for Clinical Pharmacology, Department of Anesthesiology, Washington University School of Medicine, St. Louis, USA
4 shared publications- Brian K. Kobilka
Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA
4 shared publications - Jonathan F. Fay
Department of Biochemistry and Molecular Biology, University of Maryland Baltimore, Baltimore, MD, USA
4 shared publications
Latest Publications
- Open Access
- 27 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (13) , eaeb6737
Mechanistic insights into the therapeutic properties of delta opioid receptor
The delta opioid receptor (DOR) is a promising target for treating pain, anxiety, and depression, yet no DOR-based drugs have reached the clinic. Here, we examine how ligands with varying therapeutic properties modulate DOR function. While full agonists rapidly internalize the receptor, partial agonists show a slower rate of internalization, and antagonists increase cell-surface DOR levels. High-resolution structures of ligand-bound DOR-G i1 complexes, including those with antagonists engaged, reveal key interactions that account for DOR ligand selectivity, potency, and efficacy. Single-molecule fluorescence resonance energy transfer studies show that DOR dynamically samples three distinct states (active, obligate preactive, and inactive), and transition rates are tuned by both ligand efficacy and G protein coupling. The endogenous agonist, met-enkephalin, not only stabilizes the active-state conformation but also catalyzes transitions between the active and inactive states. These results reveal how ligand-specific interactions and receptor dynamics can govern pharmacological profiles and provide a framework for developing DOR-targeted therapeutics.
- 27 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (13) , eaeb6737
Open AccessMechanistic insights into the therapeutic properties of delta opioid receptor
The delta opioid receptor (DOR) is a promising target for treating pain, anxiety, and depression, yet no DOR-based drugs have reached the clinic. Here, we examine how ligands with varying therapeutic properties modulate DOR function. While full agonists rapidly internalize the receptor, partial agonists show a slower rate of internalization, and antagonists increase cell-surface DOR levels. High-resolution structures of ligand-bound DOR-G i1 complexes, including those with antagonists engaged, reveal key interactions that account for DOR ligand selectivity, potency, and efficacy. Single-molecule fluorescence resonance energy transfer studies show that DOR dynamically samples three distinct states (active, obligate preactive, and inactive), and transition rates are tuned by both ligand efficacy and G protein coupling. The endogenous agonist, met-enkephalin, not only stabilizes the active-state conformation but also catalyzes transitions between the active and inactive states. These results reveal how ligand-specific interactions and receptor dynamics can govern pharmacological profiles and provide a framework for developing DOR-targeted therapeutics.
- Open Access
- 14 December 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Discovery of BE2012, a First-in-Class REV-ERBα/β Antagonist with Favorable Selectivity and Pharmacokinetics, and In Vivo Efficacy in Inducing Key Myogenic Factors for Muscle Repair upon Acute Muscle Injury
REV-ERBα is a nuclear receptor transcriptional repressor involved in circadian rhythm, metabolism, inflammation, and myogenesis. Antagonizing REV-ERBα has emerged as a promising therapeutic strategy, yet few compounds with favorable pharmacokinetic profiles have been identified since SR8278. Here, we report the discovery and optimization of BE2012, a 3-aminoquinazolinone antagonist identified through high-throughput screening and refined via systematic structure–activity relationship studies. BE2012 exhibited potent REV-ERBα antagonism (EC₅₀ = 0.285 μM), high nuclear receptor selectivity, minimal CNS off-target interactions, and improved ADME and pharmacokinetic properties, including a 22-fold longer half-life (t₁/₂ = 3.79 h) than SR8278. Molecular modeling revealed key hydrophobic and hydrogen-bonding interactions within the REV-ERBα ligand-binding pocket that stabilize BE2012 and explain its enhanced potency. In a murine model of acute muscle injury, BE2012 upregulated myogenic transcription factors and promoted muscle repair. Collectively, BE2012 represents a selective, pharmacokinetically favorable REV-ERBα/β antagonist with therapeutic potential in muscle regeneration and related diseases.
- 14 December 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDiscovery of BE2012, a First-in-Class REV-ERBα/β Antagonist with Favorable Selectivity and Pharmacokinetics, and In Vivo Efficacy in Inducing Key Myogenic Factors for Muscle Repair upon Acute Muscle Injury
REV-ERBα is a nuclear receptor transcriptional repressor involved in circadian rhythm, metabolism, inflammation, and myogenesis. Antagonizing REV-ERBα has emerged as a promising therapeutic strategy, yet few compounds with favorable pharmacokinetic profiles have been identified since SR8278. Here, we report the discovery and optimization of BE2012, a 3-aminoquinazolinone antagonist identified through high-throughput screening and refined via systematic structure–activity relationship studies. BE2012 exhibited potent REV-ERBα antagonism (EC₅₀ = 0.285 μM), high nuclear receptor selectivity, minimal CNS off-target interactions, and improved ADME and pharmacokinetic properties, including a 22-fold longer half-life (t₁/₂ = 3.79 h) than SR8278. Molecular modeling revealed key hydrophobic and hydrogen-bonding interactions within the REV-ERBα ligand-binding pocket that stabilize BE2012 and explain its enhanced potency. In a murine model of acute muscle injury, BE2012 upregulated myogenic transcription factors and promoted muscle repair. Collectively, BE2012 represents a selective, pharmacokinetically favorable REV-ERBα/β antagonist with therapeutic potential in muscle regeneration and related diseases.
- 1 December 2025
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 393 (1) , 103787
An orally active estrogen receptor–related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity
- 1 December 2025
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 393 (1) , 103787
An orally active estrogen receptor–related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity
- Open Access
- 13 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Structure-guided design of partial agonists at an opioid receptor
Chronic pain and opioid overdose deaths highlight the need for non-addictive analgesics with novel mechanisms. The δ opioid receptor (δOR) is a promising target, as it lacks the respiratory depression associated with µ opioid receptor (µOR) agonists. However, early δOR full agonists caused seizures, limiting their clinical use. Partial δOR agonists may offer more controlled receptor activation than full agonists, but their development has been hindered by uncertainty regarding the molecular mechanism of partial agonism. Here we show that C6-Quino, a bitopic ligand developed through structure-based design, acts as a selective δOR partial agonist. Functional studies reveal that C6-Quino shows differential activity at G-protein and arrestin pathways and interacts with the sodium binding pocket, confirmed through cryo-EM analysis. C6-Quino demonstrates oral activity, analgesic activity in chronic pain models without causing δOR-related seizures and µOR-related adverse effects which have limited opioid usage in recent times. This discovery outlines a new strategy for developing δOR-targeted analgesics and provides a framework for optimizing signaling profiles of other Class A GPCRs.
- 13 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Open AccessStructure-guided design of partial agonists at an opioid receptor
Chronic pain and opioid overdose deaths highlight the need for non-addictive analgesics with novel mechanisms. The δ opioid receptor (δOR) is a promising target, as it lacks the respiratory depression associated with µ opioid receptor (µOR) agonists. However, early δOR full agonists caused seizures, limiting their clinical use. Partial δOR agonists may offer more controlled receptor activation than full agonists, but their development has been hindered by uncertainty regarding the molecular mechanism of partial agonism. Here we show that C6-Quino, a bitopic ligand developed through structure-based design, acts as a selective δOR partial agonist. Functional studies reveal that C6-Quino shows differential activity at G-protein and arrestin pathways and interacts with the sodium binding pocket, confirmed through cryo-EM analysis. C6-Quino demonstrates oral activity, analgesic activity in chronic pain models without causing δOR-related seizures and µOR-related adverse effects which have limited opioid usage in recent times. This discovery outlines a new strategy for developing δOR-targeted analgesics and provides a framework for optimizing signaling profiles of other Class A GPCRs.
- Top Cited Papers
- 5 March 2025
- Published by Springer Nature in Nature
- Vol. 640 (8057) , 265-273
A cryptic pocket in CB1 drives peripheral and functional selectivity
The current opioid overdose epidemic highlights the urgent need to develop safer and more effective treatments for chronic pain1. Cannabinoid receptor type 1 (CB1) is a promising non-opioid target for pain relief, but its clinical use has been limited by centrally mediated psychoactivity and tolerance. We overcame both issues by designing peripherally restricted CB1 agonists that minimize arrestin recruitment. We achieved these goals by computationally designing positively charged derivatives of the potent CB1 agonist MDMB-Fubinaca2. We designed these ligands to occupy a cryptic pocket identified through molecular dynamics simulations—an extended binding pocket that opens rarely and leads to the conserved signalling residue D2.50 (ref. 3). We used structure determination, pharmacological assays and molecular dynamics simulations to verify the binding modes of these ligands and to determine the molecular mechanism by which they achieve this dampening of arrestin recruitment. Our lead ligand, VIP36, is highly peripherally restricted and demonstrates notable efficacy in three mouse pain models, with 100-fold dose separation between analgesic efficacy and centrally mediated side effects. VIP36 exerts analgesic efficacy through peripheral CB1 receptors and shows limited analgesic tolerance. These results show how targeting a cryptic pocket in a G-protein-coupled receptor can lead to enhanced peripheral selectivity, biased signalling, desired in vivo pharmacology and reduced adverse effects. This has substantial implications for chronic pain treatment but could also revolutionize the design of drugs targeting other G-protein-coupled receptors.
- 5 March 2025
- Published by Springer Nature in Nature
- Vol. 640 (8057) , 265-273
Top Cited PapersA cryptic pocket in CB1 drives peripheral and functional selectivity
The current opioid overdose epidemic highlights the urgent need to develop safer and more effective treatments for chronic pain1. Cannabinoid receptor type 1 (CB1) is a promising non-opioid target for pain relief, but its clinical use has been limited by centrally mediated psychoactivity and tolerance. We overcame both issues by designing peripherally restricted CB1 agonists that minimize arrestin recruitment. We achieved these goals by computationally designing positively charged derivatives of the potent CB1 agonist MDMB-Fubinaca2. We designed these ligands to occupy a cryptic pocket identified through molecular dynamics simulations—an extended binding pocket that opens rarely and leads to the conserved signalling residue D2.50 (ref. 3). We used structure determination, pharmacological assays and molecular dynamics simulations to verify the binding modes of these ligands and to determine the molecular mechanism by which they achieve this dampening of arrestin recruitment. Our lead ligand, VIP36, is highly peripherally restricted and demonstrates notable efficacy in three mouse pain models, with 100-fold dose separation between analgesic efficacy and centrally mediated side effects. VIP36 exerts analgesic efficacy through peripheral CB1 receptors and shows limited analgesic tolerance. These results show how targeting a cryptic pocket in a G-protein-coupled receptor can lead to enhanced peripheral selectivity, biased signalling, desired in vivo pharmacology and reduced adverse effects. This has substantial implications for chronic pain treatment but could also revolutionize the design of drugs targeting other G-protein-coupled receptors.
- Open Access
- 16 July 2024
- Published by Springer Nature in Research Square
Structure-Guided Design of Partial Agonists at an Opioid Receptor
The persistence of chronic pain and continuing overdose deaths from pain-relieving opioids targeting µ opioid receptor (µOR) have fueled the need for reliable long-term analgesics which use different targets and mechanisms. The δ opioid receptor (δOR) is a potential alternative target for non-addictive analgesics to alleviate chronic pain, made more attractive by its lack of respiratory depression associated with µOR agonists. However, early δOR full agonists were found to induce seizures, precluding clinical use. Partial δOR agonists may offer more controlled activation of the receptor compared to full agonists, but the development of such ligands has been hindered by uncertainty over the molecular mechanism mediating partial agonism. Using a structure-based approach, we explored the engagement of the sodium binding pocket in δOR and developed a bitopic ligand, C6-Quino, predicted to be a selective δOR partial agonist. Functional studies of C6-Quino revealed that it displayed δOR partial agonist activity at both G-protein and arrestin pathways. Its interaction with the sodium pocket was confirmed and analyzed using a single particle cryo-EM. Additionally, C6-Quino demonstrated favorable chemical and physiological properties like oral activity, and analgesic activity in multiple chronic pain models. Notably, µOR-related hyperlocomotion and respiratory depression, and δOR-related convulsions, were not observed at analgesic doses of C6-Quino. This fundamentally new approach to designing δOR ligands provides a blueprint for the development of partial agonists as safe analgesics and acts as a generic method to optimize signaling profiles of other Class A GPCRs.
- 16 July 2024
- Published by Springer Nature in Research Square
Open AccessStructure-Guided Design of Partial Agonists at an Opioid Receptor
The persistence of chronic pain and continuing overdose deaths from pain-relieving opioids targeting µ opioid receptor (µOR) have fueled the need for reliable long-term analgesics which use different targets and mechanisms. The δ opioid receptor (δOR) is a potential alternative target for non-addictive analgesics to alleviate chronic pain, made more attractive by its lack of respiratory depression associated with µOR agonists. However, early δOR full agonists were found to induce seizures, precluding clinical use. Partial δOR agonists may offer more controlled activation of the receptor compared to full agonists, but the development of such ligands has been hindered by uncertainty over the molecular mechanism mediating partial agonism. Using a structure-based approach, we explored the engagement of the sodium binding pocket in δOR and developed a bitopic ligand, C6-Quino, predicted to be a selective δOR partial agonist. Functional studies of C6-Quino revealed that it displayed δOR partial agonist activity at both G-protein and arrestin pathways. Its interaction with the sodium pocket was confirmed and analyzed using a single particle cryo-EM. Additionally, C6-Quino demonstrated favorable chemical and physiological properties like oral activity, and analgesic activity in multiple chronic pain models. Notably, µOR-related hyperlocomotion and respiratory depression, and δOR-related convulsions, were not observed at analgesic doses of C6-Quino. This fundamentally new approach to designing δOR ligands provides a blueprint for the development of partial agonists as safe analgesics and acts as a generic method to optimize signaling profiles of other Class A GPCRs.
- Top Cited Papers
- 3 July 2024
- Published by Springer Nature in Nature
- Vol. 631 (8021) , 686-693
A µ-opioid receptor modulator that works cooperatively with naloxone
The µ-opioid receptor (µOR) is a well-established target for analgesia1, yet conventional opioid receptor agonists cause serious adverse effects, notably addiction and respiratory depression. These factors have contributed to the current opioid overdose epidemic driven by fentanyl2, a highly potent synthetic opioid. µOR negative allosteric modulators (NAMs) may serve as useful tools in preventing opioid overdose deaths, but promising chemical scaffolds remain elusive. Here we screened a large DNA-encoded chemical library against inactive µOR, counter-screening with active, G-protein and agonist-bound receptor to ‘steer’ hits towards conformationally selective modulators. We discovered a NAM compound with high and selective enrichment to inactive µOR that enhances the affinity of the key opioid overdose reversal molecule, naloxone. The NAM works cooperatively with naloxone to potently block opioid agonist signalling. Using cryogenic electron microscopy, we demonstrate that the NAM accomplishes this effect by binding a site on the extracellular vestibule in direct contact with naloxone while stabilizing a distinct inactive conformation of the extracellular portions of the second and seventh transmembrane helices. The NAM alters orthosteric ligand kinetics in therapeutically desirable ways and works cooperatively with low doses of naloxone to effectively inhibit various morphine-induced and fentanyl-induced behavioural effects in vivo while minimizing withdrawal behaviours. Our results provide detailed structural insights into the mechanism of negative allosteric modulation of the µOR and demonstrate how this can be exploited in vivo.
- 3 July 2024
- Published by Springer Nature in Nature
- Vol. 631 (8021) , 686-693
Top Cited PapersA µ-opioid receptor modulator that works cooperatively with naloxone
The µ-opioid receptor (µOR) is a well-established target for analgesia1, yet conventional opioid receptor agonists cause serious adverse effects, notably addiction and respiratory depression. These factors have contributed to the current opioid overdose epidemic driven by fentanyl2, a highly potent synthetic opioid. µOR negative allosteric modulators (NAMs) may serve as useful tools in preventing opioid overdose deaths, but promising chemical scaffolds remain elusive. Here we screened a large DNA-encoded chemical library against inactive µOR, counter-screening with active, G-protein and agonist-bound receptor to ‘steer’ hits towards conformationally selective modulators. We discovered a NAM compound with high and selective enrichment to inactive µOR that enhances the affinity of the key opioid overdose reversal molecule, naloxone. The NAM works cooperatively with naloxone to potently block opioid agonist signalling. Using cryogenic electron microscopy, we demonstrate that the NAM accomplishes this effect by binding a site on the extracellular vestibule in direct contact with naloxone while stabilizing a distinct inactive conformation of the extracellular portions of the second and seventh transmembrane helices. The NAM alters orthosteric ligand kinetics in therapeutically desirable ways and works cooperatively with low doses of naloxone to effectively inhibit various morphine-induced and fentanyl-induced behavioural effects in vivo while minimizing withdrawal behaviours. Our results provide detailed structural insights into the mechanism of negative allosteric modulation of the µOR and demonstrate how this can be exploited in vivo.
- Open Access
- 6 December 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-17
Design and structural validation of peptide–drug conjugate ligands of the kappa-opioid receptor
Despite the increasing number of GPCR structures and recent advances in peptide design, the development of efficient technologies allowing rational design of high-affinity peptide ligands for single GPCRs remains an unmet challenge. Here, we develop a computational approach for designing conjugates of lariat-shaped macrocyclized peptides and a small molecule opioid ligand. We demonstrate its feasibility by discovering chemical scaffolds for the kappa-opioid receptor (KOR) with desired pharmacological activities. The designed De Novo Cyclic Peptide (DNCP)-β-naloxamine (NalA) exhibit in vitro potent mixed KOR agonism/mu-opioid receptor (MOR) antagonism, nanomolar binding affinity, selectivity, and efficacy bias at KOR. Proof-of-concept in vivo efficacy studies demonstrate that DNCP-β-NalA(1) induces a potent KOR-mediated antinociception in male mice. The high-resolution cryo-EM structure (2.6 Å) of the DNCP-β-NalA–KOR–Gi1 complex and molecular dynamics simulations are harnessed to validate the computational design model. This reveals a network of residues in ECL2/3 and TM6/7 controlling the intrinsic efficacy of KOR. In general, our computational de novo platform overcomes extensive lead optimization encountered in ultra-large library docking and virtual small molecule screening campaigns and offers innovation for GPCR ligand discovery. This may drive the development of next-generation therapeutics for medical applications such as pain conditions.
- 6 December 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-17
Open AccessDesign and structural validation of peptide–drug conjugate ligands of the kappa-opioid receptor
Despite the increasing number of GPCR structures and recent advances in peptide design, the development of efficient technologies allowing rational design of high-affinity peptide ligands for single GPCRs remains an unmet challenge. Here, we develop a computational approach for designing conjugates of lariat-shaped macrocyclized peptides and a small molecule opioid ligand. We demonstrate its feasibility by discovering chemical scaffolds for the kappa-opioid receptor (KOR) with desired pharmacological activities. The designed De Novo Cyclic Peptide (DNCP)-β-naloxamine (NalA) exhibit in vitro potent mixed KOR agonism/mu-opioid receptor (MOR) antagonism, nanomolar binding affinity, selectivity, and efficacy bias at KOR. Proof-of-concept in vivo efficacy studies demonstrate that DNCP-β-NalA(1) induces a potent KOR-mediated antinociception in male mice. The high-resolution cryo-EM structure (2.6 Å) of the DNCP-β-NalA–KOR–Gi1 complex and molecular dynamics simulations are harnessed to validate the computational design model. This reveals a network of residues in ECL2/3 and TM6/7 controlling the intrinsic efficacy of KOR. In general, our computational de novo platform overcomes extensive lead optimization encountered in ultra-large library docking and virtual small molecule screening campaigns and offers innovation for GPCR ligand discovery. This may drive the development of next-generation therapeutics for medical applications such as pain conditions.
- Open Access
Negative allosteric modulation of the µ-opioid receptor
The µ-opioid receptor (µOR) is a well-established target for analgesia, yet conventional opioid receptor agonists cause serious adverse effects, notably addiction and respiratory depression, which have led to the present opioid overdose epidemic. µOR negative allosteric modulators (NAMs) may serve as powerful tools in preventing opioid overdose deaths, but promising chemical scaffolds remain elusive. We screened a large DNA-encoded chemical library against inactive µOR, counter-screening with active, G-protein and agonist bound receptor to “steer” selections toward functional negative allosteric modulators. We discovered a NAM compound with high and selective enrichment to inactive µOR; the molecule potently blocks the activity of orthosteric agonists and enhances the affinity of the key opioid overdose reversal molecule, naloxone. It accomplishes this by binding to a site on the extracellular vestibule proximal to naloxone, stabilizing a unique inactive conformation of the extracellular portions of the second and seventh transmembrane helices. The NAM perturbs orthosteric ligand kinetics in therapeutically desirable ways and works cooperatively with low doses of naloxone in vivo to inhibit morphine-induced antinociception, respiratory depression and conditioned place preference while minimizing withdrawal behaviors. Our results provide detailed structural insights into the mechanism of a negative allosteric modulator for the µOR and demonstrate how it can be exploited in vivo .
Open AccessNegative allosteric modulation of the µ-opioid receptor
The µ-opioid receptor (µOR) is a well-established target for analgesia, yet conventional opioid receptor agonists cause serious adverse effects, notably addiction and respiratory depression, which have led to the present opioid overdose epidemic. µOR negative allosteric modulators (NAMs) may serve as powerful tools in preventing opioid overdose deaths, but promising chemical scaffolds remain elusive. We screened a large DNA-encoded chemical library against inactive µOR, counter-screening with active, G-protein and agonist bound receptor to “steer” selections toward functional negative allosteric modulators. We discovered a NAM compound with high and selective enrichment to inactive µOR; the molecule potently blocks the activity of orthosteric agonists and enhances the affinity of the key opioid overdose reversal molecule, naloxone. It accomplishes this by binding to a site on the extracellular vestibule proximal to naloxone, stabilizing a unique inactive conformation of the extracellular portions of the second and seventh transmembrane helices. The NAM perturbs orthosteric ligand kinetics in therapeutically desirable ways and works cooperatively with low doses of naloxone in vivo to inhibit morphine-induced antinociception, respiratory depression and conditioned place preference while minimizing withdrawal behaviors. Our results provide detailed structural insights into the mechanism of a negative allosteric modulator for the µOR and demonstrate how it can be exploited in vivo .
- Open Access
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 538
Structure based approaches on fentanyl template to design novel mu opioid modulators
ID 52769 Poster Board 538 Opioids are used for the treatment of acute to severe pain. Usage of opioids also produces liabilities like respiratory depression and addiction, which in combination with illicit use of fentanyl and designer analogs has contributed to the opioid epidemic. Most approaches to design safer opioids have been restricted to targeting the orthosteric binding sites. We have recently reported a novel strategy to design functionally selective opioids by targeting the sodium binding allosteric site in the mu opioid receptor (MOR). The lead ligand C6 guano engages a key residue Asp2.50 in the sodium site through a salt bridge with a guanidine group in the ligand. C6 guano shows MOR dependent antinociception with reduced adverse effects seen with clinically used opioids (Faouzi et al., Nature 2023, 613, 767–774). While representing a significant advance in the design of opioids, C6 guano is supraspinally active because of the polar and charged guanidine group. Using the cryo-EM structure of C6 guano bound to MOR, we designed second generation analogs to optimize the systemic activity of C6 guano. Characterization of analogs led to the identification of a fentanyl-derived compound named RO-76 which in TRUPATH assays showed reduced efficacy at all Gi/o/z subtypes and no measurable efficacy at β-arrestin-1/2 and labelled unique transducers in APEX2 proximity labeling assays. Unlike C6 guano which showed direct engagement of the sodium site, RO-76 interacted with the sodium site residues through a water in cryo-EM of RO-76 bound to MOR-Gi complex. Previous high-resolution structures of MOR have predicted the presence of a polar cavity in the sodium binding pocket, but these waters have not been rationally targeted before at MOR or other GPCRs to the best of our knowledge. In mice, the drug was systemically active in tail withdrawal assays, and showed reduced respiratory depression and conditioned place preference compared to morphine. In summary, we envision that targeting the sodium binding site may be a potential avenue to both probe the role of the sodium site in MOR function as well as development of a new class of analgesics in the near future. Support and sponsors: Center for Clinical Pharmacology University of Health Sciences and Pharmacy at St. Louis National Institute of Drug Abuse
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 538
Open AccessStructure based approaches on fentanyl template to design novel mu opioid modulators
ID 52769 Poster Board 538 Opioids are used for the treatment of acute to severe pain. Usage of opioids also produces liabilities like respiratory depression and addiction, which in combination with illicit use of fentanyl and designer analogs has contributed to the opioid epidemic. Most approaches to design safer opioids have been restricted to targeting the orthosteric binding sites. We have recently reported a novel strategy to design functionally selective opioids by targeting the sodium binding allosteric site in the mu opioid receptor (MOR). The lead ligand C6 guano engages a key residue Asp2.50 in the sodium site through a salt bridge with a guanidine group in the ligand. C6 guano shows MOR dependent antinociception with reduced adverse effects seen with clinically used opioids (Faouzi et al., Nature 2023, 613, 767–774). While representing a significant advance in the design of opioids, C6 guano is supraspinally active because of the polar and charged guanidine group. Using the cryo-EM structure of C6 guano bound to MOR, we designed second generation analogs to optimize the systemic activity of C6 guano. Characterization of analogs led to the identification of a fentanyl-derived compound named RO-76 which in TRUPATH assays showed reduced efficacy at all Gi/o/z subtypes and no measurable efficacy at β-arrestin-1/2 and labelled unique transducers in APEX2 proximity labeling assays. Unlike C6 guano which showed direct engagement of the sodium site, RO-76 interacted with the sodium site residues through a water in cryo-EM of RO-76 bound to MOR-Gi complex. Previous high-resolution structures of MOR have predicted the presence of a polar cavity in the sodium binding pocket, but these waters have not been rationally targeted before at MOR or other GPCRs to the best of our knowledge. In mice, the drug was systemically active in tail withdrawal assays, and showed reduced respiratory depression and conditioned place preference compared to morphine. In summary, we envision that targeting the sodium binding site may be a potential avenue to both probe the role of the sodium site in MOR function as well as development of a new class of analgesics in the near future. Support and sponsors: Center for Clinical Pharmacology University of Health Sciences and Pharmacy at St. Louis National Institute of Drug Abuse